BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Genzyme  Europe  B.V.  submitted  on  4  March  2002  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) through the 
centralised  procedure  for  Aldurazyme,  which  was  designated  as  an  orphan  medicinal  product 
(EU/3/01/022) on 14 February 2001. 
The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were: 
Rapporteur:  Dr I. Hudson 
Co-Rapporteur:  Dr E. Abadie 
Orphan Drugs: 
Aldurazyme (laronidase) was designated as an orphan medicinal product in the following indication: 
treatment of Mucopolysaccharidosis, type I. 
Scientific Advice: 
The company did not seek scientific advice at the CPMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 26 March 2002. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 6 June 2002. 
The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 10 June 
2002. 
During  the  meeting  on  23  –  25  July  2002  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the company. The final consolidated List of Questions was sent to the 
company on 26 July 2002. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
12 September 2002. 
The summary reports of the inspections carried out at the manufacturing sites were issued on 30 
September  2002  (Hollister-Stier  Laboratories  LLC,  Spokane,  USA),  13  December  2002 
(Genzyme Corp., Framingham, USA) and on 10 January 2003 (BioMarin Pharmaceutical Inc, 
Novato CA, USA and Genzyme Corporation, Allston, USA). 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 23 October 2002. 
During the meeting on 19 – 21 November 2002 the CPMP adopted a list of outstanding issues 
to be addressed by the company in writing and if necessary during an oral explanation. The list 
of outstanding issues was sent to the company on 22 November 2002. 
The company provided written information on these outstanding issues to all CPMP members 
on 12 December 2002.  
The  Rapporteur/Co-Rapporteurs’  joint  review  on  the  company’s  responses  to  the  list  of 
outstanding issues was circulated to all CPMP members on 10 January 2003. 
In the margin of the CPMP meeting on 21 - 23 January 2003, an ad-hoc clinical expert meeting 
took place on 20 January 2003 and a report was adopted by the CPMP on 21 January 2003.   
1/2 
EMEA 2004 
 
 
 
 
 
 
 
 
 
• 
• 
• 
During  the  CPMP  meeting  on  21-23  January  2003,  it  was  decided  that  in  the  light  of  the 
outcome of the ad hoc expert meeting there was no longer any need for the company to address 
outstanding issues during an oral hearing before the CPMP. 
During  the  meeting  on  18  –  20  February  2003  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting  a  Marketing  Authorisation  under  exceptional  circumstances  to  Aldurazyme  on 
20 February 2003. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 10 June 2003. 
2/2 
EMEA 2004 
 
 
